Sharenet Sites 
Sharenet Sites
SKJ - Sekunjalo Investments Limited - Genius Biotherapeutics ("GBT") granted permission to obtain a primary listing on a foreign stock exchange Sekunjalo Investments Limited (Incorporated in the Republic of South Africa) Registration number 1996/006093/06 Share code: SKJ ISIN: ZAE000017893 ("Sekunjalo" or "the Company") GENIUS BIOTHERAPEUTICS ("GBT") GRANTED PERMISSION TO OBTAIN A PRIMARY LISTING ON A FOREIGN STOCK EXCHANGE Genius Biotherapeutics (AKA Bioclones), South Africa`s leading Biotechnology company at the forefront of novel technology treatment for cancer and infectious diseases announces that it has received permission from the Minister of Finance of South Africa and the South African Reserve Bank to obtain a primary listing on a foreign stock exchange. Genius is delighted that the Minister has approved the request by Genius Biotherapeutics to obtain an offshore primary listing on either the London Stock Exchange ("LSE") or NASDAQ, including the externalisation of up-front listing costs amounting to R20 million. The uniqueness of the biotechnology business and the funding constraints in South Africa make the biotechnology listing important for Genius to commercialise its 23 global patents and enter into clinical trials for overseas markets. Dr Iqbal Surve, Chairman of GBT has said that the listing permission will allow South Africa to benefit from capital investments, employment creation, increased revenues and taxes and will also create numerous opportunities for young South African scientists to be part of the global scientific community and to be at the cutting edge of novel technologies in cancer treatment. The approval was granted subject to a number of conditions. GBT has been working with its international shareholders, scientific partners and licensors to ensure that the conditions can be fulfilled. GBT is now able to report that it has full endorsement from its international shareholders from Europe as well as its global strategic partner from Switzerland, Solidago. Solidago AG, the European licensor to GBT and pharmaceuticals multinationals of its Biosimiliar portfolio will assist GBT in its international expansion and listing plans. Dr Gianluigi Musinelli Chairman of Solidago has stated "that he believes that Genius will put African biotechnology on the global map and looks forward to partnering GBT its novel cancer therapeutics". Dr Surve has said that the model of investing in biotech is one which requires substantial capital, scientific resources, world-class tertiary institutions, and innovative and low cost scientific base. South Africa has all and through the permission for the offshore listing will enable GBT to raise valuable investment capital in the biotech global markets. Dr Surve has said that GBT will follow up on its international road show to London and New York of a year ago with the appointment of a major investment bank (which has experience of having listed biotechnology companies of billions of dollars of value). This investment bank will advise and prepare the company for the listing and the preferred stock exchange of LSE or the NASDAQ. GBT shareholders will be advised accordingly. Cape Town 12 April 2012 Sponsor PSG Capital Date: 12/04/2012 12:45:01 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.
